Sylvester establishes Neuroendocrine Tumors Program; Aman Chauhan named leader

Florida leukemia rates rising rapidly as population ages, study shows

Driven by a steady influx of retirees, Florida now has the highest leukemia rates of any U.S. state and the disease is the fastest-rising cancer type statewide, according to research from Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.

March 14, 2025

Vol.51 No.10

Clinical Roundup

Roswell Park team discovers treatment target for neuroendocrine prostate cancer

A team of researchers at Roswell Park Comprehensive Cancer Center led by Dhyan Chandra has discovered a new therapeutic target for neuroendocrine prostate cancer, a rare and hard-to-treat form of prostate cancer.

January 10, 2025

Vol.51 No.01

Art exhibit at University of Miami Sylvester bridges North and South America

“Bridge to Bahia” exhibit.Source: Sylvester Comprehensive Cancer CenterKaren Estrada, a survivor of acute myeloid leukemia, used visual art to communicate with her two boys while undergoing a bone marrow transplant at Sylvester Comprehensive Cancer Center. Because Estrada’s treatment required isolation, and her young children could not yet read and write, she sought out other creative vessels to foster closeness between them.

December 13, 2024

Vol.50 No.46

By Claire Marie Porter

Clinical Roundup

Antibody shows encouraging results for treating high-risk follicular lymphoma and marginal zone lymphoma

Two clinical trials testing the antibody Zynlonta (loncastuximab tesirine) showed encouraging results in patients with high-risk forms of two blood cancers – follicular lymphoma and marginal zone lymphoma.

December 13, 2024

Vol.50 No.46

Drugs & Targets

Daiichi Sankyo, Merck collaborate to develop and commercialize MK-6070, an investigational delta-like ligand 3 targeting T-cell engager

Daiichi Sankyo and Merck have expanded their existing global co-development and co-commercialization agreement for three investigational DXd antibody-drug conjugates to include Merck’s MK-6070, an investigational delta-like ligand 3 targeting T-cell engager.

August 09, 2024

Vol.50 No.32

In Brief

Kenneth Griffin gifts $50M to Sylvester Comprehensive Cancer Center to help fund cancer research building

Kenneth C. Griffin, founder and CEO of Citadel and founder of Griffin Catalyst, gifted $50 million to Sylvester Comprehensive Cancer Center to help fund a 12-story, 244,000-square-foot cancer research building.

March 08, 2024

Vol.50 No.10